JPRN-UMIN000006616已完成未知
PRevention of End stage kidney disease by Darbepoetin Alfa In CKD patients with non-diabeTic kidney disease. - PREDICT
PREDICT steering committee0 个研究点目标入组 440 人开始时间: 2011年10月27日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 440
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Diabetes (HbA1c 6.4% IFCC) 2) CKD patients treated with ESA other than epoetins. 3) CKD patients treated with epoetin 36000 IU or more. 4) Hypertension (180/10mmHg and higher) 5) Heart failure (NYHA III and IV) 6) malignancy, hematological disorder 7) malnuturition 8) Active and continuous gastrointestinal tract bleeding 9) ANCA associated glomerulonephritis, acute infection, active SLE 10) CKD patients who will be started dialysis or will receive tranplantation 11) Myocardial infarction within last 6 months 12) Stroke or plumonary embolism within last 12 months 13) Severe allergy 14) Pregnant woman or CKD patients who wish to be pregnant 15) Allergy against erythropoetin 16) CKD patients who is not appropriate to entry the clincal trial
研究者
相似试验
已完成
3 期
PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney DiseaseChronic Kidney DiseaseDiabetesNCT01581073Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan476
已完成
4 期
The prevention effect in renal disease patients taking a oral steroid with the rebamipide or the rabeprazole- a randomized control studyRenal diseaseJPRN-UMIN000001611Graduate School of Medicine Science, Kumamoto University50
招募中
1 期
Therapy for prevention of renal failure using mesenchymal stem cells cultured in serum-free mediumDiabetic kidney disease, IgA nephropathy, NephrosclerosisChronic kidney diseaseJPRN-jRCTb060220083akashima Ayumu10
尚未招募
2 期
Protective effect of kidney by low dose of darbepoetin alfa in patients with chronic kidney diseaseJPRN-UMIN000008984Chiba university hospital, Nephrology40
已完成
不适用
The prevention of progression in CKD of medication adherence to AST-120 in patients with non-dialysis chronic kidney disease (CKD) and significance of measurement indoxyl sulfate as an indicator of medication adherencenon-dialysis chronic kidney diseaseJPRN-UMIN000023724Jichi Medical University100